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Available online 20 July 2016Neural stem cells and progenitor cells (NPCs) are increasingly appreciated to hold great promise for regenerative
medicine to treat CNS injuries and neurodegenerative diseases. However, evidence for effective stimulation of
neuronal production from endogenous or transplanted NPCs for neuron replacement with small molecules
remains limited. To identify novel chemical entities/targets for neurogenesis, we had established a NPC
phenotypic screen assay and validated it using known small-molecule neurogenesis inducers. Through screening
small molecule libraries with annotated targets, we identiﬁed BET bromodomain inhibition as a novel
mechanism for enhancing neurogenesis. BET bromodomain proteins, Brd2, Brd3, and Brd4 were found to be
downregulated inNPCs upon differentiation,while their levels remain unaltered inproliferating NPCs. Consistent
with the pharmacological study using bromodomain selective inhibitor (+)-JQ-1, knockdown of each BET
protein resulted in an increase in the number of neurons with simultaneous reduction in both astrocytes and
oligodendrocytes. Gene expression proﬁling analysis demonstrated that BET bromodomain inhibition induced
a broad but speciﬁc transcription program enhancing directed differentiation of NPCs into neurons while
suppressing cell cycle progression and gliogenesis. Together, these results highlight a crucial role of BET proteins
as epigenetic regulators in NPC development and suggest a therapeutic potential of BET inhibitors in treating
brain injuries and neurodegenerative diseases.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Neurogenesis
Gliogenesis
Neural progenitor cells
BET bromodomain
Small molecule inhibitor
I-BET
JQ-1
Epigenetics1. Introduction
Remarkable progress has beenmade in the research and application
of neural stem cells (NSCs) and progenitor cells (NPCs) demonstrating
their tremendous potential for stem-cell based cell therapy or targeting
endogenous NPCs to treat CNS injury and neurodegenerative diseases
(Gage and Temple, 2013; Goldman et al., 2012; Gupta et al., 2012; Lu
et al., 2012; Ming and Song, 2011). New opportunities have emerged
to discover neural regenerative therapeutics towards signiﬁcant
unmet medical needs. However, many challenges still remain. For
example, in injured CNS and under disease conditions, transplanted
NPCs preferentially become astrocytes (Aboody et al., 2011; Reekmansoad, Zhangjiang Hi-tech Park,
MA02210.
. This is an open access article underet al., 2012; Robel et al., 2011). Small molecules that modulate the
developmental processes of NSCs or NPCs towards desired cell fate not
only offer signiﬁcant opportunities for therapeutic drugs targeting
endogenous NPCs for repair and regeneration, but also could enhance
the efﬁcacy of NSC transplantation for neuronal replacement (Li et al.,
2013).
Once committed to a certain cell fate, NPCs undergo cell cycle arrest
and terminal differentiation leading to the exhibition of cell-type-
speciﬁc features. NPC differentiation including neurogenesis and
gliogenesis is a highly orchestrated process that is tightly regulated via
both extrinsic environmental signals and intrinsic changes in gene
expression and epigenetic regulation. Several crucial signaling
pathways including Wnt, Notch and the bone morphogenetic proteins
(BMPs) pathway have been identiﬁed in regulating the development
of NPCs (Faigle and Song, 2013; Kriegstein and Alvarez-Buylla, 2009).
The interplay of transcription factors and epigenetic modiﬁers,
including histone modiﬁcations, DNA methylation and microRNAs
during development is essential for NPCs to control self-renewal, fatethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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et al., 2010). Suppression of astrocytic lineage genes during the neuro-
genic phase is one of the key cell-intrinsic epigenetic mechanisms
underlying fate speciﬁcation (Kanski et al., 2014; Sun et al., 2001).
Recent studies have identiﬁed many different types of epigenetic
regulators, including polycomb group and trithorax group proteins,
DNA-damage inducible protein 45b, methyl-CpG-binding protein
MBD1, DNA methyltransferases, histone deacetylases (HDACs) and
acetyltransferases (HATs), which are involved in the tight regulation
of the proliferation and speciﬁcation of NPCs or the differentiation and
maturation of newborn neurons (Lim et al., 2009; Ma et al., 2010; Wu
et al., 2010; Zhao et al., 2003). In the case of histone modiﬁcations,
extensive studies have now illustrated the important role of the histone
code in methylation and acetylation, epigenetic writers ( HATs) and
erasers (HDACs) in neurogenesis (Hsieh et al., 2004; Merson et al.,
2006; Montgomery et al., 2009; Prozorovski et al., 2008; Yu et al.,
2009). However, little is known about epigenetic readers in the
development of NPCs and neurogenesis.
The bromodomain and extraterminal (BET) family of bromodomain-
containing proteins (Brds), including Brd2, Brd3, Brd4, and testis-
speciﬁc BrdT, are epigenetic readers of the acetylation histone code on
chromatin. The two tandem bromodomains of BET proteins bind acety-
lated lysine in histone N-terminal tails. The binding is proposed to assist
the recruitment and passage of RNA polymerase II co-regulatory com-
plexes facilitating transcription of target genes (Belkina and Denis,
2012; Filippakopoulos and Knapp, 2014; Loven et al., 2013; Nicodeme
et al., 2010; Shi and Vakoc, 2014). BET proteins regulate expression of
multiple genes of therapeutic relevance, including those involved in
tumor cell growth, inﬂammatory response, and cardiac hypertrophy
(Anand et al., 2013; Delmore et al., 2011; Filippakopoulos et al., 2010;
Nicodeme et al., 2010). The understanding of BET biology has been
greatly accelerated by the discovery of selective, small-molecule
inhibitors of BET bromodomains that speciﬁcally disrupt the interaction
between BET proteins and acetylated histones (Chung et al., 2011;
Filippakopoulos et al., 2010; Gosmini et al., 2014; Nicodeme et al.,
2010). BET bromodomain inhibitors (I-BET) have been used to probe
BET function in a number of developmental and disease contexts, such
as spermatogenesis, infection, cancer, and heart failure (Anand et al.,
2013; Asangani et al., 2014; Dawson et al., 2011; Henssen et al., 2013;
Matzuk et al., 2012; Nicodeme et al., 2010; Puissant et al., 2013; Wyce
et al., 2013). Recently, I-BET, included in a small-molecule cocktail
that can directly convert ﬁbroblasts into neurons, was proposed
to play a role in disrupting the ﬁbroblast-speciﬁc program during
reprogramming (Li et al., 2015). However, the direct role of BET
bromodomain proteins in NPC development, particularly NPC differen-
tiation, remains less well characterized.
In this study, we discovered BET bromodomains as a novel target for
neurogenesis through a NPC phenotypic screen aimed to identify drug-
like small molecules inducing neuronal differentiation. We provide
evidence that BET bromodomain proteins are critical players in NPC
development including cell cycle progression, fate speciﬁcation and
cell differentiation. BET bromodomain inhibition induces a broad but
speciﬁc transcription program promoting neurogenesis while simulta-
neously inhibiting gliogenesis. Our study establishes a rationale for
using BET inhibitors to enhance neuronal differentiation efﬁcacy in
regenerative cell therapy.
2. Materials and methods
2.1. NPC culture, proliferation and differentiation assay
Mouse NPCs were isolated, cultured and passaged as described in
Kim et al. (Kim et al., 2012). Brieﬂy, NPCs from E12 mouse cortices
were isolated and expanded in DMEM/F12 containing 2% of B27-
supplement and 10 ng/ml of basic ﬁbroblast growth factor (bFGF).
NPCs of passage 3 were used in all assays.For proliferation assay, NPCswere expanded in the presence of bFGF
(10 ng/ml) reﬁlled daily to the culture medium. For differentiation
assay, NPC were allowed to differentiate spontaneously in the absence
of bFGF for 5 days. Cells were then subject to Immunocytochemistry
staining. Neurons, astrocytes and oligodendrocyte lineage were
immunno-labeled with Tuj1, GFAP and Olig2 antibody, respectively.
Immunocytochemistry images were scanned and analyzed by using
Cellomics (Target Activation V4 algorithm, ArrayScan VTI 700, Thermo
Fisher Scientiﬁc,MA, USA), or Acumen (Composite populationmanager,
Explorer X3, TTP LabTech, Royston, UK) automated high content
imaging and analysis platforms.
2.2. Compound Screening, dose-response series and curve ﬁtting
GlaxoSmithKline's focused compound libraries (~8300 compounds
with target annotation) were used for NPC differentiation phenotypic
screen. Primary screen was carried out in single shot (1 μM of each
compound in 0.01% DMSO) and 3 replicates in the format of 384-well
plates. Each plate had tool compound and 0.01% DMSO as positive and
negative control, respectively. Primary hits were deﬁned as the
compounds that promote neuronal differentiation by at least 3 SD
above the fold change of Tuj1+ cell percentage relative to control
DMSO. Primary hits were subject to 8-point or 10-point dose-response
studies with series dilution of compound in triplicates. Dose-response
curves were generated from XL ﬁt (IDBS, Burlington, MA, USA)
using the dose-response onsite formula as follows: ﬁt = (A + (B /
(1+ ((x/C)^D)))); inv= ((((B/(y – A)) – 1)^(1/D)) ∗ C); res= (y− ﬁt).
2.3. Time-resolved ﬂuorescence resonance energy transfer titrations
(TR-FRET)
Test compounds were titrated against pre-coupled Bromodomain
fragment and tetra-acetylated histone H4 (1−21) peptide as previous-
ly described (Chung et al., 2011). The interaction of Brds and histone
peptide was determined using Time Resolved FRET.
2.4. Immunocytochemistry
Cells were ﬁxed by 4% paraformaldehyde for 20min, washed 3 times
with phosphate-buffer (PBS) and proceeded as described in Xu et al.
(Xu et al., 2013). The following primary antibodies were used: anti-
Tuj1(Millipore, MAB1637), anti-GFAP(DAKO, Z0334), and anti-Olig2
(Millipore, MABN50).
2.5. Immunoblotting
Western Blotting was performed using the following antibodies:
Anti-Brd2 (Bethyl Laboratories, A302-583A), anti-Brd3 (Bethyl Labora-
tories, A302-368A), and anti-Brd4 (Bethyl Laboratories, A301-985A),
monoclonal anti-β-actin-peroxidase clone AC-15 (Sigma, A3854).
2.6. Construction of Brd shRNA, generation of lentivirus and NPC infection
Mouse Brd2, 3 and 4 small hairpins RNA (shRNA) (Zuber et al.,
2011) DNA constructs (Supplemental Table S1) were cloned in
pLVX-shRNA2 vector (Clontech, Mountain View, CA, USA). The knock-
down constructs with the following speciﬁc sequences for Brd2 (5′-
GAAACATCGTGGCCGAATT-3′), Brd3 (5′-TTTATGATAATCAGGCAGGTTC-
3′), and Brd4 (5′-TTTGTTGATATCTAGACTTAGC-3′) were validated and
selected by DNA sequencing and western blotting. Lentivirus production
and titer test were carried out following the previously published
protocol (Crittenden et al., 2007). Infections were carried out in
proliferating NPC at a M.O.I of 15 for 48 h. Media containing virus was
then removed and changed to differentiation media. All the virus related
experiments were approved by the Genetically Modiﬁed Organism
Management Committee of GSK R&D China.
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NPCswere treated with (+)-JQ-1 or (−)-JQ-1 at 0.2 μMor 0.5 μM in
differentiation medium for 12 and 24 h. Total RNA was isolated using
RNeasyMini Kit (Qiagen, Valencia, CA) and sent to Beijing Genomics In-
stitute (BGI) Tech Solutions for library construction and sequencing
(HiSeq2000 sequencing platform, Illumina, CA, USA). Following quality
control to raw data using “fastqc” (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/), RNA-seq reads were aligned to
mouse genome (mm9) using TopHat2 (ref: 23618408). The gene ex-
pression was quantiﬁed using RPKM values from cufﬂink analysis
using NCBI RefSeq gene annotation. Hierarchical clustering and princi-
pal component analysis were performed to all samples based on the
similarity of their expression proﬁles. Using these clustering, we exam-
ined the effects of treatments on gene expression. The differentially
expressed genes (DEGs) between samples with (+)- JQ1 or (−)-JQ-1
treatment were found using cuffdiff. The thresholds for the DEGs
were: Fold change ≥1.5 and FDR ≤ 0.05. Then, DEGs fromeach treatment
were applied for functional enrichment and pathway analysis using
MetaCore (https://portal.genego.com). Using all expressed genes as
the background, DEGswere evaluated for their enrichment to biological
processes and pathways. At a cutoff of p ≤ 0.01, we selected the enriched
ones and used these terms to describe the functional or processes
association.
2.8. qRT-PCR of total RNA
RNA from NPC samples was subject to RT-qPCR as previously
described (Xu et al., 2013). The primer sequences were listed in Supple-
mental Table S2.
2.9. Quantiﬁcation and statistical analysis
The studies were carried out in at least 3 independent experiments
and/or 3 replicates. For quantiﬁcation of ShRNA knockdown effect on
NPC differentiation, immuno-stained cells were imaged from 27 ﬁelds
per shRNA construct. Each ﬁeld had 400–600 GFP+ cells. The numbers
of Tuj1+, GFAP+, or Olig2+ cells were counted among the total number
of GFP+ cells in each ﬁeld. The data were presented as mean ± SEM in
the ﬁgures. Unpaired student's t-test or two-way ANOVA with
Bonferroni post-tests were used to evaluate the signiﬁcance of differ-
ences between means. In all cases, signiﬁcance was noted at *P b 0.05,
**P b 0.01, ***P b 0.001.
3. Results
3.1. Neurogenesis phenotypic screening identiﬁed BET-bromodomain
inhibitors
To identify small molecules that selectively direct NPC differentia-
tion into neurons, we previously developed a high-content imaging
assay based on the induction of neuronal marker Tuj1 expression in
differentiated NPCs, and validated it using GSK 3β inhibitors (Kim et
al., 2012). Primary embryonic mouse cortical NPCs proliferate in vitro
when cultured in serum-free basal media containing FGF. Nestin+
primary NPCs were passaged twice to expand the limited amount of
starting material and to enrich self-renewing Nestin+ progenitor
population while depleting any differentiated cells that remained after
dissection. Upon removal of FGF, Nestin+ NPCs cease to proliferate,
and undergo spontaneous differentiation giving rise to neurons, and
glial cells including astrocytes and oligodendrocytes (Kim et al., 2012),
which could be identiﬁed using the cell type speciﬁc markers, Tuj1,
GFAP and Olig2, respectively. In this assay that had been optimized for
high-throughput chemical genomics screen, small molecule com-
pounds were added to NPCs at the time of FGF withdrawal. Upon
5 days of NPC differentiation, the cells were labeled with Tuj1 antibodyto detect neurons, scanned and quantiﬁed using Acumen or Cellomics
automated high-content imaging and analysis platform (Fig. 1A). The
percentage of Tuj1+ cells in total cell number (Tuj1+%) was quantiﬁed
as the readout for neurogenesis. As commonly observed in cell-based
high-throughput assays, variations in the assay readout in 0.01%
DMSO vehicle controls were observed among individual wells, plates,
cell preparations, and cell batches. Therefore, the average of Tuj1+%
for 0.01% DMSO vehicle controls per 384-well plate was used as the
baseline reference. All compound data were normalized and shown as
the fold change of Tuj1% relative to DMSO control.
To identify the compounds that direct neuronal differentiation, we
screened N8000 compounds using highly selective compound libraries
with known target associations and broad target coverage at 1 μM
screening concentration in triplicates. These compounds were derived
from different libraries including Biologically Diverse Compound Set,
which is structurally enriched to cover various target classes. Positive
hitswere deﬁned as the compounds that enhanced Tuj1+ cell formation
by at least 3 SD above the mean of DMSO control (Fig. 1B). Among the
primary hits, 30 actives were further conﬁrmed by concentration-
response analysis that showed a concentration-dependent and repro-
ducible effect, representing a hit rate of ~0.37%. Out of 30 conﬁrmed
hits, 21 hits were annotated as BET-bromodomain inhibitors (I-BET).
I-BET is a novel class of chemical tools recently identiﬁed to selectively
inhibit the binding of bromodomain of BET family bromodomain
proteins to acetylated lysines in histone resulting in alterations on chro-
matin recognition and transcription throughmodulating the epigenetic
function of the acetyl-lysine reading process. The neurogenic effect and
the concentration-response of representative I-BET compounds are
shown in Fig. 1C. The EC50s of active exemplar compounds was in the
range of 80 nM and 100 nM. To examine whether the neurogenic
effect of I-BET in NPCs correlates with its biochemical binding afﬁnity
of BET proteins, we prioritized 17 compounds that have diverse
structures and showed activity within a 2 log range of pEC50 potency
in independent experimental repeats for evaluation in a time-resolved
ﬂuorescence resonance energy transfer (TR-FRET) assay (Chung et al.,
2011). The pIC50s of I-BET in TR-FRET assay were determined. The
pEC50 of BET inhibitors in neuronal differentiation showed a signiﬁcant
correlation with the pIC50 of I-BET in binding analysis (R2 = 0.57,
p-value = 0.00043, Fig. 1D). Collectively, using a chemical genomic
screen we identiﬁed a number of novel selective BET inhibitors as
effective neurogenesis inducers.
3.2. The expression of Brd2, Brd3, and Brd4 is down-regulated in NPC upon
differentiation
To understand how Brds are involved in NPC development, and
inhibition of BET bromodomain induces neuronal differentiation, we
examined the expression of Brds in NPCs. Given BrdT is speciﬁcally
expressed in testis (Shang et al., 2004), we assessed the expression of
Brd2, Brd3, and Brd4 of BET family in the proliferating and differentiat-
ing NPCs. Brd2, Brd3 and Brd4 were highly expressed in proliferating
NPCs. There was no signiﬁcant change in the expression of Brds in
proliferating NPCs (Fig. 2A), while the expression level of Brd2, Brd3,
and Brd4 were markedly decreased upon differentiation and had a
trend of continuous decreasewith time (Fig. 2B). These results indicated
that the down-regulation of BETs is associated with the initiation and
progression of NPC differentiation.
3.3. BET inhibition promotes neurogenesis while blocking gliogenesis
To validate the role of Brds in NPC development, we generated and
validated lentiviral vectors expressing small hairpin RNAs (shRNAs)
that target Brd2, Brd3, and Brd4 respectively (Zuber et al., 2011) to
knock-down its expression in mouse NPCs (Fig. S1). The lentiviral vec-
tor expressing irrelevant shRNA was the control. These viral vectors
co-expressed green ﬂuorescent protein (GFP) for the identiﬁcation
Fig. 1. Identiﬁcation of BET-bromodomain inhibitors as the hits for neurogenesis through a NPC based phenotypic screen. A) Overview of the assay concept and the workﬂow of
neurogenesis phenotypic screen. ICC, Immunocytochemistry. B) Scatter plot of primary screening results shown as the fold change of differentiated neuronal population (Tuj1+%)
compared to DMSO vehicle control (green). The primary hits, which increased neuronal population by at least 3 SD, are shown in magenta. C) Concentration-response curves of two
exemplar BET-bromodomain inhibition hit compounds. EC50 values are indicated. D) Neurogenesis potency correlates with in vitro binding afﬁnity of BET proteins. Plot of mean
neurogenesis assay pEC50 against pIC 50 of Brd4 bromodomain ﬂuorescence resonance energy transfer binding assay, for 17 compounds with diverse structures tested in both assays,
showing excellent correlation (R2 = 0.57, p-value = 0.00043). DMIO, dimethyl isoxazole derivatives; THQ, tetrahydroquinoline derivatives; MTZ, methyltriazole derivatives; DMP,
dimethyl pyrazole derivatives.
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Fig. 2. Expression of Brd2, Brd3, and Brd4 during NPC proliferation and differentiation in vitro. A) RepresentativeWestern blots and relative expression quantiﬁcation of BET proteins and
β-actin (loading control) in proliferating NPCs at 1, 3 and 5 day in vitro. B) RepresentativeWestern blots and relative expression quantiﬁcation of BET proteins in NPC upon FGFwithdraw
(0 d), and at 1, 3 and 5 day in vitro differentiation. Quantiﬁcation data were mean ± SEM from 3 independent replicates, *P b 0.001 versus 0 d were determined by unpaired t-test.
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of cell differentiation following the knockdown of Brds, differentiated
cells infectedwith lentiviral vectorswere immunostained for cell-linage
markers. Quantiﬁcation of the percentage of differentiated neurons
(Tuj1+), astrocytes (GFAP+), or oligodendrocytes (Olig2+) in the total
number of GFP+ cells revealed that the knockdown of Brd2, Brd3, and
Brd4 enhanced NPC differentiation towards neurons. Interestingly,
knocking down of Brds in NPCs also signiﬁcantly inhibited the
formation of astrocytes and oligodendrocytes after differentiation
(Fig. 3). To further validate a dual role of BET silencing in gliogenesis
and neurogenesis, we used (+) JQ-1, a structurally distinct widely
used and now well validated tool compound for BET bromodomain in-
hibition, to assess the effect of BET inhibition in NPC differentiation.
(+)-JQ-1 promoted neurogenesis at similar concentrations seen with
other I-BET compounds, while also inhibiting the differentiation into
astrocytes and oligodendrocytes reproducibly in a concentration-dependent manner (Fig. 4). (−)-JQ-1, an inactive enantiomer for BET
bromodomain binding, had no signiﬁcant effect on NPC differentiation
(Fig. S2). Together, both genetic (shRNA) and pharmacological (JQ-1)
studies conﬁrmed our ﬁnding from the phenotypic screen and further
validated the dual role of BET bromodomains in both neurogenesis
and gliogenesis.
3.4. BET Bromodomain inhibition results in transcriptional changes that
suppress cell cycle progression and gliogenesis while favoring neurogenesis
To determine how the inhibition of BET bromodomain regulates NPC
development and differentiation, we treated the NPCs with 0.2 μM or
0.5 μM of (+)- JQ-1 or (−)-JQ-1 for 12 h or 24 h in independent tripli-
cates and subjected to whole genome transcriptomic analysis by RNA
Sequencing (RNA-seq). Unsupervised hierarchical clustering clearly
segregated the samples by treatment (+)-JQ-1 vs. (−)-JQ-1 (Fig. S3).
Fig. 3. shRNA knockdown of Brd2, Brd3, and Br4 enhances neuronal differentiationwhile inhibiting the generation of astrocytes and oligodendrocytes. A) Representative immunostaining
images of differentiatedNPC following lentiviral shRNA transduction (labeled by GFP). The differentiation of neuron, astrocyte and oligodendrocyte lineagewas labeled by Tuj1, GFAP, and
Olig2 respectively. Scale bar, 50 μm. B) Quantiﬁcation of differentiated neuron, astrocyte and oligodendrocyte populations for NPC transduced with lentiviral shRNA targeting Brd2, Brd3,
and Brd4 respectively relative to control shRNA. Data were mean± SEM from 3 independent replicates with 9 ﬁelds per replicate for each shRNA construct. Each ﬁeld had 400–600 GFP+
cells. *P b 0.001 versus control shRNA were determined by unpaired t-test.
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number of upregulated genes, (+)-JQ-1 treatment produced suppres-
sion of signiﬁcant number of genes (Fig. 5A, a and a’, 82 upregulated
vs. 871 downregulated genes in 0.5 μM, 24 h-treatment group by 1.5-
fold or greater, FDR b 0.05). With increased (+)-JQ-1 concentration or
time in treatment, the number of differential gene expression increased
(Fig. 5A, a’, 531 vs. 871 downregulated genes in 0.2 μM or 0.5 μM dose
group at 24 h treatment; b’, 398 vs. 475 downregulated genes that are
common in both 0.2 μM and 0.5 μM dose group at 12 h or 24 h treat-
ment), with a large degree of overlap between the two concentrations
or time points (Fig. 5A). To understand the biological relevance of
these expression changes, we performed functional process and path-
way analyses using Metabase. Gene Ontology Biological Process (GO)
analysis displayed an enrichment of key processes involved in
neurogenesis, cytoskeleton rearrangement, cell adhesion, Notch and
Wnt signaling, transcriptional and translational regulation, and cell
cycle, which are known processes for NPC proliferation, fate speciﬁca-
tion and differentiation (Fig. 5B) (Faigle and Song, 2013; Gotz and
Huttner, 2005). Further functional pathway analysis using Metabase
identiﬁed a number of statistically signiﬁcant signaling pathway catego-
ries, including neural stem cell lineage commitment, the differentiation
of oligodendrocyte and astrocyte, EGFR, and PTEN signaling pathways
(Fig. 5C). Among these processes and pathways,we identiﬁed represen-
tative highly characterized genes for neurogenesis, astrogenesis,
gliogenesis, cell cycle and key regulators in NPC development and fate
speciﬁcation. Consistent with the phenotype of NPC in response to
BET inhibition, proneurogenic genes including DLX2, BCL6, PROX were
upregulated by (+)-JQ-1, while genes related to cell cycle progression(CDKN1C, CCND1, MYC, MYCN), glial fate speciﬁcation (NKX2, SOX10,
BMP4 and receptor), differentiation of astrocytes (MAPK3, ID1, ID3,
S100B, ALDH1A1) and oligodendrocytes (PDGFα and receptors,
Cspg4/NG2, PLP1, MBP, MAG) were signiﬁcantly downregulated
(Fig. S4). Quantitative real-time PCR analysis of NPC treated with
0.5 μMof (+)-JQ-1 for 12 h or 24 h further validated the similar pattern
on signiﬁcant changes of gene expression (Fig. 5D).
Collectively, these data demonstrated BET bromodomain inhibition
induced broad but speciﬁc transcriptional programs which inhibit cell
cycle progression and gliogenesis but promote neurogenesis.
4. Discussion
Phenotypic screens have led to the discovery of many ﬁrst-in-class
drugs (Swinney and Anthony, 2011). However, a signiﬁcant challenge
with phenotypic screenings is to determine the molecular target of
the compounds. Target deconvolution could be a time-consuming and
complicated process with limited success rate (Schenone et al., 2013).
Among small molecules identiﬁed from previous neurogenesis pheno-
typic screens, the P7C3 neuroprotective chemical class was identiﬁed
from an impressive in vivo chemical screen for hippocampal
neurogenesis in mice (Pieper et al., 2010). With photocrosslinking and
various biochemical methods, nicotinamide phosphoribosyltransferase
was recently identiﬁed as the intracelluar target of P7C3 (Wang et al.,
2014). Through a cell-based phenotypic screen, Isoxazole stem cell
modulators were identiﬁed to trigger neuronal differentiation through
a neurotranmitter-evoked Ca2+ signal (Schneider et al., 2008). Howev-
er, the precise target of isoxazole in NPC remains unknown. To identify
Fig. 4. BET-bromodomain inhibitor (+)-JQ-1 induces neuronal differentiation of NPC while blocking glial differentiation towards astrocytes and oligodendrocytes. A) Representative
immunostaining images of differentiated NPC treated with (+)-JQ-1 at indicated concentration. The differentiation of neuron, astrocyte and oligodendrocyte lineage was labeled by
Tuj1, GFAP, and Olig2 respectively. Scale bar, 50 μm. B) Full dose-response curves of (+)-JQ-1 on NPC differentiation into neuron, astrocyte and oligodendrocyte compared to vehicle
control. EC50 values were indicated. Data were mean ± SEM from 3–5 replicates.
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vent any potential issues associated with target deconvolution, we used
GSK high-quality proprietary compound libraries that not only have
broad target coverage but the compounds for each annotated target is
highly selective. Through this primary NPC based phenotypic screen,
we discovered that BET bromodomain-containing proteins are the
novel target for neurogenesis. Using highly potent and selective chemi-
cal probes and shRNA knockdown, our study provided pharmacologic
and genetic validation of BET bromodomains as a target for
neurogenesis. Importantly, our genome wide transcriptome analysis
on changes induced by selective bromodomain inhibitor (+)-JQ-1
revealed that BET inhibition is sufﬁcient for initiating transcriptional
programs that promote neurogenesis while repress gliogenesis and
cell cycle progression, shedding light on the mechanistic basis of BET
proteins as epigenetic readers in NPC development and neurogenesis.
Among four BET proteins described in vertebrates, Brd2, Brd3 and
Brd4 are expressed in the CNS (Shang et al., 2004). The exact role of
BET family in the development and proper functioning of the brain
and how their dysfunction might contribute to neurological disorders
remain elusive. Previous genetic studies on bromodomain-containing
proteins suggested a role of BET proteins in neural development
(Gyuris et al., 2009; Shang et al., 2009). However, their widespread
expression during development and early embryonic lethality hindered
a thorough study of BET proteins in NPC development and neuronal
differentiation (Gyuris et al., 2009; Houzelstein et al., 2002; Shang etal., 2009). Pleiotrophin (Ptn), an intracelluar antagonist of Brd2 that
can destabilize the association of Brd2 with chromatin has recently
been identiﬁed to play a role in the transition from neural progenitor
cell proliferation to differentiation (Garcia-Gutierrez et al., 2014).
Endogenous regulators like Ptn that mediate BET-directed epigenetic
program are yet to be discovered to have a better understanding the
role of BET proteins in health and various diseases. On the other hand,
chemical biology approach as highlighted in the discovery of small
molecule inhibitors of BET bromodomains could be a powerful tool to
advance our biological understanding and to discover potentially
novel therapeutics (Bunnage et al., 2013). Using chemical biology
techniques we identiﬁed BET bromodomains as a novel target for
neurogenesis through a phenotypic screen of small-molecule libraries,
but also revealed the role of BET proteins in NPC development and
potential applications of BET inhibitors as an adjunct in regenerative
medicine.
Once committed to a certain cell fate, NPC undergo cell cycle arrest
and terminal differentiation leading to the exhibition of cell-type-
speciﬁc features. The onset and processes of neuronal and astroglial
differentiation involve extensive chromatin remodeling and precise
regulation of transcription (Hirabayashi and Gotoh, 2010). Epigenetic
enzymes including epigenetic writers and erasers, and small molecules
that can target some of the enzymes have been demonstrated to induce
the alternations of a large array of gene expression and the modulation
of multiple neural development pathways during these processes
Fig. 5. BET inhibition induces broad but speciﬁc transcriptional programs in NPC during differentiation. A) Venn analyses showing up-regulated, down-regulated and overlapped
differentially expressed genes (DEGs) following treatment of NPC with 0.2 μM and 0.5 μM of (+)-JQ-1 for 12 h, 24 h compared to inactive enantiomer (−)-JQ-1. a and a’, up-regulated
(a), down-regulated (a’) DEGs in 24 h treatment of 0.2 μM, 0.5 μM of (+)-JQ-1 and the overlapped subset between 2 concentrations; b and b’, up-regulated (b), down-regulated (b’)
DEGs that are common in both 0.2 μM and 0.5 μM treatment group at 12 h, 24 h and the overlapped subset between 12 h and 24 h treatment. B) Global biological process (GO)
analysis of DEGs enriched in NPCs treated with (+)-JQ-1. C) Global functional pathway (MetaBase) analysis of DEGs enriched in NPCs treated with (+)-JQ-1. The color grade of the
heat maps in both B and C indicates the statistical signiﬁcance, which describes the enrichment of DEGs in a deﬁned subset of genes associated with a particular biological process
term or functional pathway annotation. D) Quantitative RT-PCR analyses of key regulatory genes involved in gliogenesis, neurogenesis and cell cycle progression in NPC, which were
treated with 0.5 μM of (+)-JQ-1 for 12 h, 24 h. Relative fold change compared to (−)-JQ-1 were shown. Data shown as mean ± SEM were from 3 independent studies with 3
replicates each study. *P b 0.05, **P b 0.01, ***P b 0.001 versus control (−)-JQ-1 were determined by unpaired t-test.
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were found to induce neuronal differentiation of NPC, whereas it
inhibited astrocyte and oligodendrocyte differentiation. VPA treatment
upregulated proneurogenic genes NeuroD and Neurogenins (Ngn)
through promoting recruiting Actylated-H4 to their promoters for tran-
scriptional activation (Hsieh et al., 2004; Yu et al., 2009). BET proteins as
epigenetic readers bind acetylatedhistones and are a crucial regulator of
transcription inmany cell types. Brd4, awell-studiedmember of theBET
family, was found to recruit transcriptional regulatory complexes in-
cluding P-TEFb andMediators to acetylated chromatin thereby coupling
the acetylation state of chromatin with Pol II elongation. Interestingly,
global transcriptomic analyses on the effects of BET bromodomain
inhibitors revealed that the transcriptional effects of BET inhibitors are
often highly speciﬁc to the cell type and/or the physiology and
pathophysiology process being examined (Shi and Vakoc, 2014). For
example, treatingmacrophage cells with I-BET prevented the activation
of a speciﬁc subset of LPS-inducible genes that encode cytokines,
chemokines and various transcription factors involved in the inﬂamma-
tory response. In the absence of LPS stimulation, I-BET treatment led to
minimal changes to global gene expression in macrophages, indicating
selective effects of BET inhibitors on inﬂammatory genes in this cell
type (Nicodeme et al., 2010). In NPC among the genes regulated by
(+)-JQ-1, biological process and pathway analyses revealed that
bromodomain inhibition leads to the most signiﬁcant changes in NSC
lineage commitment, the differentiation of oligodendrocytes and astro-
cytes, neurogenesis, and the processes and signaling pathways associat-
ed with NPC development. A signiﬁcantly large number of genes were
downregulated, which are likely to be the direct and secondary targets
of BETs as a result of their function as transcriptional activators (Shi
and Vakoc, 2014). Both astroglial and oligodendroglial differentiation
pathways were signiﬁcantly perturbed in response to (+)-JQ-1 treat-
ment, and the expression of their downstream target genes weremark-
edly suppressed. Bone morphogenetic proteins (BMPs) are known to
promote glial differentiation and inhibit neuronal fate speciﬁcation
(Bonaguidi et al., 2005; Lim et al., 2000). BMPs mainly potentiate JAK/
STAT signaling through the formation of a STAT-SMAD co-activating
complex (Faigle and Song, 2013). Platelet-derived growth factor
(PDGF) is not only a mitogen for the proliferation of oligodendrocyte
progenitor cells, but also an instructional signal for the differentiation
of neural stem cells into oligodendrocyte lineage (Fruttiger et al.,
1999; Hu et al., 2008). During the neurogenic phase of NPC develop-
ment, suppression of alternative fates while promotion of neurogenesis
are knownmechanisms for neuronal fate speciﬁcation (Sunet al., 2001).
(+)-JQ-1 induced suppression of transcriptions on these lineage
speciﬁcation signals (for example BMP and PDGF) and downstream
genes towards the differentiation and maturation of astrocyte and oli-
godendrocyte might directly contribute to the inhibition of gliogenesis
and promotion of neuronal differentiation. Moreover, (+)-JQ1 treat-
ment induced increased gene expression involved in chromatin assem-
bly, epigenetic regulation and neurogenesis. Distal-less homeobox 2
(Dlx2) is a helix-loop-helix transcription factor that is heavily controlled
by epigenetic modiﬁcations (Lim et al., 2009). Over-expression of Dlx2
is required for GABAergic neuron production. It negatively regulates
Oligo2-dependent oligodendrocyte formation (Brill et al., 2008;
Petryniak et al., 2007; Suh et al., 2009). Bcl6, an oncogene in B lympho-
cytes encoding a BTB/POZ zinc ﬁnger transcription repressor, was
recently identiﬁed as a proneurogenic genenecessary for proper cortical
neurogenesis and pyramidal neuron differentiation through selective
regulation of Notch-dependent transcription (Tiberi et al., 2012). The
“cell cycle length hypothesis”, in vitro and in vivo studies suggested
that inhibition of the cell cycle favors neurogenesis and prevents prolif-
eration of NPCs (Arai et al., 2011; Gotz and Huttner, 2005; Knoepﬂer et
al., 2002). Consistent with this hypothesis, accompanied with increased
neuronal differentiation, the transcriptions of Cdkn1C, CyclinD1, Myc
and MycN genes that are involved in cell cycle progression were mark-
edly suppressed by (+)-JQ-1 treatment. The genome-wide analysis ofBrd4 chromatin occupancy using chromatin immunoprecipitation
coupledwith DNA sequencing (CHIP-Seq) showed that Brd4 is associat-
ed with essentially all active promoters and a signiﬁcant fraction of
active enhancers in the genome of various normal and transformed
cell types (Anand et al., 2013; Loven et al., 2013). Examination of Brd4
occupancy at genes whose transcription is particularly sensitive to
(+)-JQ-1 has led to the observation that such genes often exhibit high
levels of Brd4 occupancy at nearby super enhancer regions. The associ-
ation of high-level of Brd4 occupancy with these lineage-speciﬁc
enhancers has been linked to the lineage-speciﬁc gene regulation by
BET inhibition (Shi and Vakoc, 2014). Future study on CHIP-seq analysis
of (+)-JQ-1 treated differentiating NPC might be able to identify these
enhancer elements that are selectively targeted by BET inhibition and
underlie the effects of I-BET in NPC development.
Neural stem cell transplantation is currently investigated as a treat-
ment for different CNS injuries and disorders. One key challenge for a
successful cell therapy is that an inﬂammatory environment in the
diseased CNS might trigger glial differentiation of transplanted NSCs or
NPCs (Aboody et al., 2011; Reekmans et al., 2012; Robel et al., 2011).
Additionally, there might be a safety concern on the oncogenic potential
of human iPSC-derived NSCs. Previous studies on BET bromodomain
inhibition have demonstrated profound anti-proliferative and anti-
inﬂammatory effects (Belkina and Denis, 2012). Our study provided
new evidence on a dual role of BET inhibition in promoting neurogenesis
and suppressing gliogenesis. Together it suggests a potential clinical
application of I-BET in neural stem cell therapy for enhanced efﬁcacy
and improved safety in cell-based transplantation.
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